Comparative Pharmacology
Head-to-head clinical analysis: COACTIN versus MYCITRACIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COACTIN versus MYCITRACIN.
COACTIN vs MYCITRACIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Coactin (mecillinam) is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding protein 2 (PBP2) in gram-negative bacteria, leading to the formation of spheroplasts and cell lysis.
MYCITRACIN is a combination of bacitracin and neomycin, which are aminoglycoside antibiotics. Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan subunits. Neomycin binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis.
400 mg orally every 6-8 hours with a full glass of water.
500 mg orally every 6 hours
None Documented
None Documented
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function; prolonged to 2-6 hours in renal impairment; clinically requires frequent dosing or dose adjustment in renal failure.
Terminal elimination half-life is 2–3 hours in adults with normal renal function. Prolonged significantly in renal impairment (up to 24–48 hours in anuria).
Renal: approximately 70-80% as unchanged drug via glomerular filtration and tubular secretion; biliary/fecal: less than 10% as metabolites and unchanged drug.
Primarily renal (glomerular filtration and tubular secretion); >90% of dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion is minimal (<5%).
Category C
Category C
Antibiotic Combination
Antibiotic Combination